Show simple item record

dc.contributor.authorIyer, Namrata
dc.contributor.authorWilliams, Michelle A.
dc.contributor.authorO’Callaghan, Amy A.
dc.contributor.authorDempsey, Elaine
dc.contributor.authorCabrera-Rubio, Raul
dc.contributor.authorRaverdeau, Mathilde
dc.contributor.authorCrispie, Fiona
dc.contributor.authorCotter, Paul D.
dc.contributor.authorCorr, Sinéad C.
dc.date.accessioned2023-09-05T11:52:19Z
dc.date.available2023-09-05T11:52:19Z
dc.date.issued2022-07-09
dc.identifier.citationIyer, N.; Williams, M.A.; O’Callaghan, A.A.; Dempsey, E.; Cabrera-Rubio, R.; Raverdeau, M.; Crispie, F.; Cotter, P.D.; Corr, S.C. Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model. Microorganisms 2022, 10, 1383. https://doi.org/10.3390/microorganisms10071383en_US
dc.identifier.urihttp://hdl.handle.net/11019/3251
dc.descriptionpeer-revieweden_US
dc.description.abstractThe use of probiotics such as Lactobacillus and Bifidobacterium spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. Lactobacillus salivarus strain UCC118TM is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 TM as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of Lactobacillus salivarius, UCC118™ in a mouse model of colitis. DSS-induced colitis was coupled with pre-treatment or post-treatment with UCC118TM by daily oral gavage. In the pre-treatment model of colitis, UCC118TM reduced the severity of the disease in the early stages. Improvement in disease severity was coupled with an upregulation of tissue IL-10 levels and increased expression of macrophage M2 markers. This anti-inflammatory activity of UCC118TM was further confirmed in vitro, using a model of LPS-treated bone marrow-derived macrophages. Taken together, these results suggest that UCC118TM may promote the resolution of inflammation. This was supported in a mouse model of established DSS-induced colitis whereby UCC118TM treatment accelerated recovery, as evidenced by weight, stool, histological markers and the recovery of microbiome-associated dysbiosis with an increased abundance of beneficial commensal species. These results demonstrate the potential of Lactobacillus salivarius UCC118TM as a probiotic-based therapeutic strategy to promote health through the upregulation of anti-inflammatory IL-10 and protect against dysbiosis during IBD.en_US
dc.description.sponsorshipScience Foundation Ireland
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofseriesMicroorganisms;Vol 10
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectprobioticen_US
dc.subjectmicrobiotaen_US
dc.subjectinflammationen_US
dc.subjectcolitisen_US
dc.titleLactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Modelen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/microorganisms10071383
dc.contributor.sponsorScience Foundation Irelanden_US
dc.contributor.sponsorEuropean Unionen_US
dc.contributor.sponsorGrantNumber11/SIRG/B2099en_US
dc.contributor.sponsorGrantNumber19/FFP/6499en_US
dc.contributor.sponsorGrantNumber754535en_US
dc.source.volume10
dc.source.issue7
dc.source.beginpage1383
refterms.dateFOA2023-09-05T11:52:21Z
dc.source.journaltitleMicroorganisms


Files in this item

Thumbnail
Name:
microorganisms-10-01383-v2.pdf
Size:
4.175Mb
Format:
PDF
Description:
main article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International